Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

Journal of Clinical Oncology

Volumn 16, Issue 2, 1998, Pages 453-461

  Dombernowsky, P ^a   Smith, I ^a   Falkson, G ^a   Leonard, R ^a   Panasci, L ^a   Bellmunt, J ^a   Bezwoda, W ^a   Gardin, G ^a   Gudgeon, A ^a   Morgan, M ^a   Fornasiero, A ^a   Hoffmann, W ^a   Michel, J ^a   Hatschek, T ^a   Tjabbes, T ^a   Chaudri, H A ^a   Hornberger, U ^a   Trunet, P F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; LETROZOLE; MEGESTROL ACETATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOVASCULAR RESPONSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WEIGHT GAIN;

EID: 0031943424     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.2.453     Document Type: Article

References (41)

1. Rose C, Mouridsen HT: Endocrine therapy of advanced breast cancer. Acta Oncol 27:721-728, 1988
2. Santen RJ, Manni A, Harvey H, et al: Endocrine treatment of breast cancer in women. Endocr Rev 11:221-265, 1990
3. Höffken K, Jonat W, Possinger K, et al: Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: A phase II study. J Clin Oncol 8:875-880, 1990
4. Evans TRJ, Di Salle E, Ornati G, et al: Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 52:5933-5939, 1992
5. Bolzmann A, Kreienberg R, Kaufmann M, et al: Phase II study of treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor atamestane. J Cancer Res Clin Oncol 118:R123, 1992(suppl, abstr)
6. Wouters W, Suoeck E, De Coster R: Vorozole, a specific nonsteroidal aromatase inhibitor. Breast Cancer Res Treat 30:89-94, 1994
7. Jonat W, Howell A, Blomqvist C, et al: A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A:404-412, 1996
8. Buzdar AU, Smith R, Vogel C, et al: Fadrozole HCl (CGS 16949A) versus megestrol acetate in postmenopausal patients with metastatic breast carcinoma. Results of two randomized double blind controlled multiinstitutional trials. Cancer 77:2503-2513, 1996
9. Bhatnagar AS, Häusler A, Schieweck K, et al: Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new nonsteroidal aromatase inhibitor. J Steroid Biochem Mol Biol 37:1021-1027, 1990
10. Bhatnagar AS, Häusler A, Schieweck K: Inhibition of aromatase in vitro and in vivo by aromatase inhibitors. J Enzyme Inhib 4:179-186, 1990
11. Trunet PF, Mueller Ph, Bhatnagar AS, et al: Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20267, in healthy male subjects. J Clin Endocrinol Metab 77:319-323, 1993
12. Iveson TJ, Smith IE, Ahern J, et al: Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab 77:324-331, 1993
13. Iveson TJ, Smith IE, Ahern J, et al: Phase I study of the oral non-steroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res 53:266-270, 1993
14. Lipton A, Demers LM, Harvey HA, et al: Letrozole (CGS 20267): A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer 75:2132-2138, 1995
15. Bisagni G, Cocconi G, Scaglione F, et al: Letrozole, a new oral non steroidal aromatase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. Ann Oncol 7:99-102, 1996
16. Tominaga T, Ohashi Y, Abe R, et al: Phase II trial of letrozole (a novel oral nonsteroidal aromatase inhibitor) in postmenopausal patients with advanced or recurrent breast cancer. Eur J Cancer 31A:S81, 1995 (suppl 5, abstr 373)
17. Dowsett M, Jones A, Johnston SRD, et al: In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with advanced breast cancer. Clin Cancer Res 1:1511-1515, 1995
18. Aaronson NK, Ahmedzai S, Bullinger M, et al: The EORTC core quality-of-life questionnaire: Interim results of an international field study, in Osaba D (ed): Effect of Cancer on Quality of Life. London, United Kingdom, CRC, 1991, pp 185-203
19. Evaluation of the cancer patient and the response to treatment, in Monfardini S, Brunner K, Crowther D, et al (eds): UICC - Manual of Adult and Paediatric Medical Oncology. Berlin, Germany, Springer, 1987, pp 22-38
20. Possinger K, Gershanovich M, Campos D, et al: Letrozole (Femara), a new potent, selective aromatase inhibitor (AI): Superior to another AI, aminoglutethimide (AG), in postmenopausal women with advanced breast cancer (ABC), after relapse or progression on previous anti-estrogen therapy. Eur J Cancer 33:S145, 1997 (suppl 8; abstr 643)
21. Muss HB, Case LD, Capizzi RL, et al: High- versus standarddose megestrol acetate in women with advanced breast cancer; A phase III trial of the Piedmont Oncology Association. J Clin Oncol 8:1797-1805, 1990
22. Cavalli F, Goldhirsch A, Jungi F, et al: Randomized trial of low-versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. J Clin Oncol 2:414-419, 1984
23. Pannuti F, Martoni A, Di Marco AR, et al: Prospective randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MPA) in the treatment of metastatic breast cancer. Eur J Cancer 15:593-601, 1979
24. Abrams JS, Cirrincione C, Aisner J, et al: A phase III dose response trial of megestrol acetate (MA) in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 11:A50, 1992(abstr)
25. Della Cuna GR, Pannuti F, Martoni A, et al: Aminoglutethimide in advanced breast cancer: Prospective, randomized comparison of two dose levels. Anticancer Res 13:2367-2372, 1993
26. Höffken K, Chacon R, Dombernowsky P, et al: Fadrozole hydrochloride (CGS 16949A), a double-blind dose-finding study in postmenopausal patients with advanced breast cancer. Ann Oncol 3:76, 1992 (suppl 5, abstr 294)
27. Buzdar A, Jonat W, Howell A, et al: Significant improved survival with Arimidex (anastrozole) versus megestrol acetate in postmenopausal advanced breast cancer: Updated results of two randomized trials. Proc Am Soc Clin Oncol 16:156a, 1997 (abstr 545)
28. Lee K, Macaulay VM, Nicholls JE, et al: An in vivo model of intratumoral aromatase using aromatase-transfected MCF7 human breast cancer cells. Int J Cancer 62:297-302, 1995
29. Lundgrunden S, Gunnersen S, Klepp R, et al: Megestrol acetate versus aminoglutethimide for metastatic breast cancer. Breast Cancer Res Treat 14:201-206, 1989
30. Willemse P, Van des Ploeg E, Sleijfer D, et al: A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer. Eur J Cancer 26:337-343, 1990
31. Canny PA, Priestmann TJ, Griffiths T, et al: Randomized trial comparing aminoglutethimide with high dose of medroxyprogesterone acetate for advanced breast carcinoma. J Natl Cancer Inst 80:1147-1151, 1988
32. Garcia-Giralt E, Aymc Y, Carton M, et al: Second and third-line hormonotherapy in advanced postmenopausal breast cancer: A multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who had become resistant to tamoxifen. Breast Cancer Res Treat 24:139-145, 1992
33. Thürlimann B, Castiglione M, Hsu-Schmitz SF, et al: Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: A phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Eur J Cancer 33:1017-1024, 1997
34. Buzdar A, Jones S, Vogel C, et al: A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer 79:730-739, 1997
35. Rose C, Freue M, Kjaer M, et al: An open, comparative randomized trial comparing formestane vs oral megestrol acetate as a second-line therapy in postmenopausal advanced breast cancer patients. Eur J Cancer 32A:49, 1996 (suppl 2, abstr PP-8-4)
36. Goss P, Wine E, Tannock I, et al: Vorozole versus Megace in postmenopausal patients with metastatic breast carcinoma who had relapsed following tamoxifen. Proc Am Soc Clin Oncol 16:155a, 1997 (abstr 542)
37. Bergh J, Bonneterre J, Illiger HJ, et al: Vorozole (Rivizor) versus aminoglutethimide (AG) in the treatment of postmenopausal breast cancer relapsing after tamoxifen. Proc Am Soc Clin Oncol 16:155a, 1997 (abstr 543)
38. Howell A, Mackintosh J, Jones M, et al: The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 24:1567-1572, 1988
39. Robertson JFR, Williams MR, Todd J, et al: Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol 25:469-475, 1989
40. Transcript of the Food and Drug Administration's Oncologic Drugs Advisory Committee meeting on Arimidex. Washington, DC, October 16, 95
41. Johannessen DC, Lønning PE: Aromatase inhibitors in malignant diseases of aging. Drugs Aging 2:530-545, 1992